-
-
-
-
-
-
-
Viatris receives Japan approval for Effexor to treat anxiety disorder
-
-
-
-
-
-
-
UBS Upgrades Viatris (VTRS) to Buy
-
-
-
-
-
-
-
Viatris to sell Biocon Biologics stake for $815 million
-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Viatris (VTRS)
-
-
-
-
-
-
-
Viatris Inc (VTRS) Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142
-
-
-
-
-
-
-
VTRS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
-
-
-
-
-
-
VTRS DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Acti
-
408,180 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

